CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day.

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases.

Bioengineering professor and The Grainger College of Engineering's Dean, Rashid Bashir, led a team of researchers in a project that's resulted in new technology that offers rapid, highly sensitive ...

Bioengineering professor and The Grainger College of Engineering's Dean, Rashid Bashir, led a team of researchers in a ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

The Chinese scientist who was imprisoned for secretly creating the world’s first genetically-engineered babies has claimed he ...

Eric Green, the longtime director of the National Human Genome Research Institute, has abruptly left his role, according to ...

German anesthesiologist Joachim Boldt has an unfortunate claim to fame. According to Retraction Watch, a public database of ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Tel Aviv University scientists say that they can inject CRISPR genetic 'molecular scissors' to shrink tumors by 90%; ...

To understand American healthcare today doesn’t require mastery of CRISPR or mRNA vaccine technology or the latest minimally invasive cardiac procedure — although these are all wonderful and ...